Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

Abroad (travel likely)RecruitingPHASE2

Conditions

Esophageal Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Tangdu Hospital Affiliated to the Fourth Military Medical University, Xi'an, Shannxi, China
Contact: Study coordinator (Xiaolong Yan, Dr) · yanxiaolong@fmmu.edu.cn · 029-847171569

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC

Esophageal Squamous Cell Carcinoma · Immunotherapy · Biomarkers

Abroad (travel likely)RecruitingPHASE2

Fuzhou, China

Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Shijiazhuang, China

Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China · Shanghai, China